Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 12Unknown 6Active not recruiting 4Recruiting 3Not yet recruiting 3Terminated 2Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Breast Neoplasms 24Colorectal Neoplasms 19Stomach Neoplasms 15Rectal Neoplasms 13Triple Negative Breast Neoplasms 10Neoplasm Metastasis 7Pancreatic Neoplasms 6Nasopharyngeal Carcinoma 6Colonic Neoplasms 6Neoplasms 4Gallbladder Neoplasms 4Cholangiocarcinoma 4Anus Neoplasms 4Adenocarcinoma Of Esophagus 4Esophageal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Somatostatinoma 2Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Klatskin Tumor 2Esophageal Squamous Cell Carcinoma 2Colorectal Cancer Metastatic 2Clinical Stage I Gastric Cancer AJCC v8 2Biliary Tract Neoplasms 2Adenoma, Islet Cell 2Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Solid Cancer 1Skin Neoplasms 1Rectal Diseases 1

Interventions

Magnetic Resonance Spectroscopy 8pembrolizumab 7Specimen Handling 7Biopsy 7Leucovorin 5Gemcitabine 5Cisplatin 5durvalumab 4Oxaliplatin 4Fluorouracil 4Capecitabine 4Paclitaxel 3Nivolumab 3Irinotecan 3Carboplatin 3tislelizumab 2olaparib 2fludarabine 2atezolizumab 2Trastuzumab 2Taxes 2Radiation Dose Hypofractionation 2Radiation 2Ipilimumab 2Cyclophosphamide 2zimberelimab 1varlilumab 1tucatinib 1tremelimumab 1surufatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Cholangiocarcinoma × Capecitabine × Clear all
NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

AstraZeneca

Phase 3 Active not recruiting
757 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Seagen Inc.

Phase 2 Active not recruiting
40 enrolled 67 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02170090 2025-03-30

ACTICCA-1

Universitätsklinikum Hamburg-Eppendorf

Phase 3 Active not recruiting
789 enrolled
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT04295317 2025-01-03

PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery

Shanghai Zhongshan Hospital

Phase 2 Active not recruiting
65 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡